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ABSTRACT
Increased lymphangiogenesis is a common feature of cancer development and 
progression, yet the influence of impaired lymphangiogenesis on tumor growth 
is elusive. C3HBA breast cancer and KHT-1 sarcoma cell lines were implanted 
orthotopically in Chy mice, harboring a heterozygous inactivating mutation of vascular 
endothelial growth factor receptor-3, resulting in impaired dermal lymphangiogenesis. 
Accelerated tumor growth was observed in both cancer models in Chy mice, coinciding 
with reduced peritumoral lymphangiogenesis. An impaired lymphatic washout was 
observed from the peritumoral area in Chy mice with C3HBA tumors, and the number 
of macrophages was significantly reduced. While fewer macrophages were detected, 
the fraction of CD163+ M2 macrophages remained constant, causing a shift towards a 
higher M2/M1 ratio in Chy mice. No difference in adaptive immune cells was observed 
between wt and Chy mice. Interestingly, levels of pro- and anti-inflammatory 
macrophage-associated cytokines were reduced in C3HBA tumors, pointing to an 
impaired innate immune response. However, IL-6 was profoundly elevated in the 
C3HBA tumor interstitial fluid, and treatment with the anti-IL-6 receptor antibody 
tocilizumab inhibited breast cancer growth. Collectively, our data indicate that 
impaired lymphangiogenesis weakens anti-tumor immunity and favors tumor growth 
at an early stage of cancer development.
INTRODUCTION
The lymphatic system is a common and early 
route of metastasis, where the occurrence of lymph node 
metastasis is a negative prognostic marker. Increased 
peritumoral lymphatic vessel density (LVD) correlates 
with increased frequency of lymph node metastasis 
and worse prognosis in various types of cancer [1–5], 
pointing to lymphatic vessels as a potential therapeutic 
target in the treatment of cancer. Various pharmacological 
inhibitors of lymphangiogenesis are currently investigated 
clinically [6–8], and the consequences of targeting tumor 
lymphangiogenesis therefore needs to be explored both in 
the early and advanced cancer setting. We addressed this 
issue by studying the early stages of cancer progression in 
Chy mice, which harbor a heterozygous inactivating point 
mutation of the tyrosine kinase domain of VEGFR-3 [9]. 
Importantly, the same mutation has been found in patients 
with hereditary lymphedema, and this model is therefore 
of particular interest in a translational context [10, 11]. Chy 
mice are characterized by impaired lymphangiogenesis in 
the dermis [10, 12], and accordingly, malignant tumors 
were implanted orthotopically in the subcutis to evaluate 
how cancer progression would be affected in a tumor 
microenvironment where the VEGFR-3 expression level 
is decreased.
We postulated that impaired lymphangiogenesis 
could increase the interstitial fluid pressure (IFP) and 
thus inhibit tumor growth by affecting the blood supply. 
Alternatively, impaired lymphangiogenesis could 
prevent tumor antigens from reaching lymph nodes, 
causing a reduced immune response and weakened 
tumor immunity. Interestingly, we found accelerated 
primary tumor growth of C3HBA breast cancer and 
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KHT-1 sarcomas in Chy mice, which was associated with 
decreased lymphatic washout and a reduced number of 
peritumoral macrophages. Apart from IL-6, reduced levels 
of all macrophage-associated cytokines were observed in 
C3HBA tumors in Chy mice, indicating an impaired innate 
immune response and potentially influencing the early 
stages of breast cancer progression.
RESULTS
Accelerated tumor growth and impaired 
peritumoral lymphangiogenesis in Chy mice
Accelerated tumor growth of orthotopically 
implanted C3HBA breast cancer and KHT-1 sarcoma 
was observed in Chy mice with impaired dermal 
lymphangiogenesis compared with wt littermates (Figure 
1A-1D). Metastases were not seen neither in regional 
lymph nodes nor in internal organs, when assessed 
macroscopically and microscopically (data not shown). 
To detect single-cell metastases, RNA was extracted 
from lung and liver tissues of mice included in the tumor 
growth trials, and RT-PCR for eGFP positive C3HBA 
tumor cells demonstrated transgene expression in the liver 
tissue of two tumor-bearing wt mice, whereas Chy mice 
had no transgene expression in these organs (Figure 1E). 
Thus, primary tumor growth was increased but an 
enhanced metastatic potential was not observed in the Chy 
model.
Next, we stained the tumor and peritumoral area 
with a LYVE-1 antibody to assess the lymphatic vessel 
density in Chy mice. Chy mice had no discernable 
lymphatics present in the peritumoral area in neither of 
the two tumor models. Wt mice had on average 30 and 8 
LYVE-1 positive lymphatic vessels per hot spot around 
C3HBA and KHT-1 tumors, respectively (Figure 1F). 
Apart from a few lymphatic vessels embedded in the outer 
tumor rim of wt mice, lymphatics could not be identified 
inside the tumor tissue.
Based on the strong tendency for lymphatic 
metastasis in the initial stages of breast cancer progression 
in humans, we assessed whether the missing lymphatics 
around C3HBA tumors affected lymph flow, measuring 
washout of labeled albumin by optical imaging [13]. 
The lymphatic drainage, assessed as washout of Alexa 
680-albumin, was significantly lower in the skin overlying 
C3HBA tumors in Chy mice, compared to wt mice 
(Figure 1G). The percentage removal of albumin per min 
from the peritumoral skin of wt mice was: -0.42 ± 0.05 
% min-1, and Chy mice: -0.18 ± 0.08 % min-1 (p=0.005). 
This demonstrates that lymphatic drainage was strongly 
impaired in the peritumoral area of C3HBA tumors 
growing in Chy mice, potentially reducing the drainage of 
tumor antigens to regional lymph nodes and migration of 
tumor cells out of the primary tumor bed [14, 15].
We measured tumor IFP by the micropuncture 
technique [16] in the outer tumor rim to assess whether 
the impaired peritumoral lymphangiogenesis affected 
the intratumoral pressure, but there was no significant 
difference in IFP between wt and Chy mice, neither in 
C3HBA nor KHT-1 tumors (Figure 1H). Since there may 
also be a pressure gradient from central to peripheral 
Figure 1: A–D. Tumor growth of C3HBA breast cancer and KHT-1 sarcoma in Chy and wt mice. A-B. Tumor growth curves depict the 
mean tumor volume ± SEM per group, from the day of measureable tumors in the mice. C–D. Days for each tumor to reach 2250 mm3 
(tumor growth time). Bars display the mean TGT ± SEM per group, demonstrating accelerated tumor growth in Chy mice. C3HBA: n=12 
mice/group. KHT-1: n=11 and n=6 in wt and Chy mice respectively.*p<0.05. (Continued )
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tumor areas, we measured IFP in the tumor center with the 
wick-in-needle (WIN) technique [17]. Again we found no 
significant difference between tumors in wt and Chy mice 
(Figure 1I). Accordingly, the impaired lymphatic drainage 
from Chy mice tumors was not caused by changes in 
intratumoral interstitial fluid pressure.
Tumor blood vessels and perfusion unaltered by 
the Chy mutation
Based on previous reports, we examined how 
heterozygous VEGFR-3 inactivation in Chy mice 
influenced tumor angiogenesis [18]. CD31 staining 
demonstrated no difference in blood vessel density 
(BVD) when C3HBA tumors in Chy and wt mice were 
compared (Figure 2A). To assess the number of perfused 
blood vessels within Chy and wt C3HBA tumors, lectin 
was injected through the tail vein and the perfused areas 
were compared, but no significant difference was found 
(Figure 2B). Thus, the accelerated primary tumor growth 
observed in the Chy model was not caused by increased 
tumor angiogenesis nor increased number of perfused 
blood vessels.
The influence of VEGFR-3 heterozygous 
inactivation on ligands of the VEGF family was assessed 
by protein analysis. VEGF-C was upregulated in C3HBA 
tumors in Chy mice (Figure 2C), which is likely the result 
of reduced VEGFR-3 expression in this mouse model. 
The other VEGFR ligands were not significantly altered 
(Figure 2C).
Figure 1: (Continued ) E. Gene expression of the eGFP-transgene, which was transduced into C3HBA breast cancer cells implanted in 
wt and Chy mice. RT-PCR of liver and lung tissue (n=5 mice per group) demonstrates metastatic C3HBA cells actively transcribing eGFP 
in the livers of two out of five wt mice (red boxes). F. LYVE-1+ lymphatics were present in the peritumoral area of wt mice, but not in Chy 
mice. Arrows point to LYVE-1+ vessels. Scale bars: 100 mm. G. Lymphatic washout assessed using Alexa 680-conjugated albumin. The 
lymphatic washout in the skin overlying C3HBA tumors in Chy mice (n=4) was significantly slower than in wt mice (n=3). **p<0.01. H. 
Intratumoral IFP measured by the micropuncture technique. There was no significant difference in IFP neither in C3HBA nor KHT-1 tumors 
implanted in wt (n=6 tumors per group) and Chy mice (n=8). Bars depict the mean ± SEM. I. Intratumoral IFP measured by the wick-in-
needle (WIN) technique. There was no significant difference in IFP neither in C3HBA nor KHT-1 tumors implanted in wt (n=9 and n=7 
tumors respectively) and Chy mice (n=2 and n=6 tumors respectively). Bars depict the mean ± SEM.
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Decreased inflammatory response and 
macrophage infiltration in Chy mice tumors
In our assessment of peritumoral lymphatics 
by LYVE-1 or VEGFR-3 staining (not shown), we 
observed scattered LYVE-1+ or VEGFR-3+ cells outside 
the lymph vessels. Based on the known expression 
of LYVE-1 or VEGFR-3 by macrophages [19, 20], 
immunohistochemistry was used to characterize this 
cell population further. We observed a reduced number 
of peritumoral F4/80+ macrophages in Chy mice and the 
total number of leukocytes (CD45+ cells) (Figure 3A) 
around C3HBA tumors was significantly reduced in 
Chy compared to wt mice. For KHT-1 tumors, a reduced 
number of peritumoral macrophages was observed in 
Chy mice, whereas the CD45+ cell count was no different 
from wt siblings (Figure 3B). To further assess the innate 
immune response, staining was performed with a CD11b 
antibody, which is a well-known marker of myeloid cells, 
including macrophages. A significant reduction in CD11b+ 
cells in Chy tumors was detected, both within the tumor 
(Figure 3D) and in the peritumoral area (Figure 3C), in 
accordance with the F4/80 staining.
The macrophages were further characterized 
by staining for CD163, a well-known marker of M2 
(alternatively activated) macrophages [21]. However, the 
number of CD163+ cells was not significantly different 
between Chy and wt mice (Figure 3E) and since the total 
Figure 2: A. Immunohistochemistry for CD31 demonstrates no difference in C3HBA intratumoral blood vessel density (BVD) between 
Chy and wt mice. Scale bars: 100 μm. Bar graph depicts the mean BVD ± SEM, n=3 per group. B. Tumor perfusion assessed by i.v. 
injection of TRITC-conjugated lectin demonstrated no difference between C3HBA tumors in Chy mice and wt mice. Scale bars: 100 μm. 
Bar graph depicts the mean number of perfused vessels per field-of-view ± SEM, n=7 per group. C. Western blot analysis of VEGF family 
ligands in whole tumor lysate from C3HBA tumors (30 μg protein/lane). VEGF-C is significantly upregulated in Chy compared to wt mice. 
Densitometry of western blots presented as the ratio of protein of interest over actin expression. Bars depict the mean ± SEM, n=3 per 
group. *p<0.05.
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number of macrophages (both M1 and M2) was reduced 
in Chy mice, this implies that less M1 macrophages were 
present in the peritumoral tissue of Chy mice, causing a 
shift towards a higher M2/M1 ratio.
To test the influence of tumor-associated 
macrophages (TAMs) on early cancer development, 
wt mice with C3HBA breast cancers were treated with 
liposomal clodronate before and during tumor initiation 
to deplete TAMs. Liposomal clodronate treatment 
inhibited tumor growth, compared to sham treatment 
(Supplementary Figure S1A), and F4/80 staining 
demonstrated a reduced number of macrophages 
(Supplementary Figure S1B). While this points to a 
pro-tumorigenic role of TAMs in general, liposomal 
clodronate treatment kills all macrophage subtypes 
unselectively [22], and do not reflect the Chy phenotype 
with a skewed M2/M1 ratio. In line with previous data 
[23], liposomal clodronate treatment reduced tumor 
angiogenesis (Supplementary Figure S1C), which may 
have contributed to the impaired tumor growth in this 
experiment. At the same time, tumor angiogenesis was 
not affected in Chy mice, demonstrating that liposomal 
clodronate treatment did not recapitulate the findings in 
these mice.
Further, we wanted to assess whether the reduced 
lymphatic washout and increased M2/M1 ratio was 
associated with altered secretion of macrophage-associated 
cytokines in Chy mice tumors. A panel of pro- and anti-
inflammatory cytokines was examined by protein analysis 
of whole C3HBA tumor lysates (Figure 3F), and apart 
from IL-6 all the pro- and anti-inflammatory cytokines 
were significantly downregulated in Chy tumors. Taken 
together, our results show a downregulated innate immune 
response in these mice.
Based on recent data alluding to the important 
role of tumor infiltrating lymphocytes (TILs) in breast 
Figure 3: A–B. Immunohistochemistry for F4/80 and CD45 in C3HBA breast cancers and KHT-1 sarcomas. (A) Significantly less 
macrophages (F4/80) and leukocytes (CD45) were observed in the peritumoral area of C3HBA tumors in Chy compared to wt mice. (B) In 
KHT-1 tumors a significantly reduced number of macrophages, but not leucocytes in general was observed in Chy compared to wt mice. 
Scale bar: 50 μm. C–D. Immunohistochemistry demonstrates significantly fewer peritumoral CD11b+ cells surrounding C3HBA (C) and 
KHT-1 tumors (D) in Chy than in wt mice. Scale bars: 100 μm. (Continued )
Oncotarget45794www.impactjournals.com/oncotarget
cancers [24], we examined the adaptive immune response 
by immunostaining for CD3 (T-lymphocytes), CD 20 
(B-lymphocytes) and FOX P3 (regulatory T-lymphocytes; 
Tregs) in C3HBA tumors (Supplementary Figure 2SA-
S2C). However, the recruitment of these cell populations 
was not affected by the Chy mutation, which was also the 
case for CD3 staining in KHT-1 tumors (Supplementary 
Figure S2D).
Increased tumor IL-6 levels in Chy mice and the 
influence of anti-IL-6 treatment
Since macrophage-associated cytokines were 
profoundly influenced by the Chy mutation in tumor 
protein lysates, we evaluated how this affected 
inflammatory mediators in the tumor interstitial fluid. 
Multiplex ELISA demonstrated that high concentrations 
of IL-6 and VEGF were present in the interstitial fluid of 
C3HBA tumors, with a significantly higher IL-6 level in 
C3HBA tumors in Chy mice than in wt mice (Figure 4A), 
thus confirming the western blot analysis for this cytokine. 
While the western blots measured the total protein content 
of cytokines within the tumors, the ELISA measured 
cytokine levels exclusively in the extracellular fluid phase. 
Thus, the discrepancy between western blots and ELISA 
for the remaining cytokines assessed may be the result of 
differential binding of secreted cytokines to extracellular 
matrix proteins or intracellular sequestration of cytokines 
that is not detected in the interstitial fluid phase [25, 26]. 
In KHT-1 sarcomas no difference was detected in IL-6 
levels between Chy mice and wt siblings (Figure 4B), 
which could be due to a high content of necrotic tissue in 
these tumors, causing spill-over of proteins between the 
intracellular and extracellular compartments.
Based on the elevated IL-6 levels in C3HBA 
tumors in Chy mice, both intracellularly and in the tumor 
interstitial fluid, we assessed the influence of the IL-6 
receptor antibody tocilizumab on tumor growth. Treatment 
with tocilizumab significantly reduced tumor growth both 
in Chy and wt mice when compared to sham treatment 
(Figure 4C). Western blot analysis of phosphorylated 
STAT3 (Ser727) confirmed that tocilizumab blocked IL-6 
downstream signaling within the tumors (Figure 4D). 
This demonstrates that IL-6 is important to C3HBA tumor 
growth, both in Chy mice and wt siblings, although the 
profound difference in IL-6 can not alone explain the 
different growth kinetics.
DISCUSSION
Increased lymphatic vessel density is associated 
with enhanced metastatic potential and poor prognosis 
[1–3]. Interestingly, we found accelerated tumor 
growth in mice with impaired lymphangiogenesis 
implanted orthotopically with C3HBA breast cancer 
or KHT-1 fibrosarcoma. In addition to reduced 
lymphatic drainage from the C3HBA breast cancers, 
Chy mice had a reduced number of macrophages, 
Figure 3: (Continued ) E. Immunohistochemistry demonstrates no significant difference in peritumoral CD163+ cells between Chy and 
wt mice. Scale bars: 100 μm. Bars graphs depict the mean number of cells per field-of-view ± SEM, n=3 per group. *p<0.05. F. Western 
blot analysis of inflammatory cytokines in whole tumor lysate from C3HBA breast cancers (30 μg protein / lane) demonstrates a global 
downregulation of pro- and anti-inflammatory cytokines in tumors growing in Chy mice, but an upregulated IL-6 level. Densitometry of 
western blots presented as the ratio of protein of interest over actin expression. Bars depict the mean ± SEM, n=3 per group. *p<0.05, 
**p<0.01.
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and in particular M1 macrophages recruited to the 
peritumoral area, indicating a weakened anti-tumor 
immune response. It is well established that tumor 
associated macrophages (TAMs) of the M2 subtype 
contribute to malignant progression and are associated 
with poor prognosis in patients with advanced cancer 
[27] whereas our results suggest that M1 macrophages 
could protect against tumor progression in the early 
stages of cancer development as seen in mice without 
the Chy mutation. Importantly though, these findings 
should be confirmed in Chy mice with spontaneous 
cancers in the future.
Figure 4: A. Multiplex ELISA of tumor interstitial fluid from C3HBA tumors demonstrating significantly higher IL-6 level in Chy 
compared to wt mice. Bars depict the mean cytokine concentration ± SEM, n=8 per group (except GM-CSF: n=3 per group). *p<0.05. 
B. ELISA of tumor interstitial fluid from KHT-1 tumors demonstrating no significant difference in IL-6 levels between Chy and wt mice. 
Bars depict the mean cytokine concentration ± SEM, n=5 per group. C. Tumor growth of C3HBA breast cancer in Chy and wt mice treated 
with either IL-6 receptor antibody (tocilizumab) or placebo (saline) i.p for 21 days. The graphs depict the mean tumor volume ± SEM, n=7 
per group. Arrows indicate when the treatment started. Tocilizumab significantly reduced tumor growth both in Chy and wt mice. *p<0.05. 
D. Western blot analysis demonstrating reduced STAT3 phosphorylation (Ser727) in C3HBA tumors when IL-6 signaling is inhibited with 
tocilizumab. Densitometry of western blots presented as the ratio of protein of interest normalized to STAT3 and actin expression. Bars 
depict the mean ± SEM, n=3 per group. *p<0.05
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While the impaired lymphangiogenesis in Chy 
mice did not affect interstitial fluid pressure inside 
C3HBA and KHT-1 tumors, lymphatic drainage from 
the peritumoral area was reduced. This is in line with a 
previous report in non-tumor bearing Chy mice [28]. 
Lymphatic peritumoral drainage transports cytokines 
and antigens to the lymph nodes to elicit an immune 
response [29], and this process is impaired in mice 
with reduced lymphangiogenesis [15]. In our study, 
less macrophages and leukocytes were recruited to the 
tumor vicinity together with a significant downregulation 
of macrophage-associated cytokines, pointing to a 
weakened innate anti-tumor immune response. This is in 
accordance with recent data demonstrating augmented 
melanoma and lymphoma growth, as well as decreased 
local lymph node inflammation, in kCYC mice with 
reduced lymphangiogenesis [15]. It has been established 
previously that the humoral immune response on the trunk 
is not influenced by the Chy mutation [28], and our current 
finding of no difference in the number of peritumoral 
adaptive immune cells between Chy and wt mice is in line 
with these observations.
Macrophages are immune cells characterized by 
heterogeneity and plasticity. The extremes of macrophage 
polarization have traditionally been simplified into M1 
(classically activated) and M2 (alternatively activated), 
but the nomenclature in this field is rapidly changing 
[30]. Evidence from both preclinical and clinical research 
present a more complex picture of macrophage activation, 
where macrophage function and balance is skewed 
depending on the surrounding stimulus [31]. TAMs, which 
exhibit M2-like features, are known inducers of cancer 
progression by stimulating angiogenesis, promoting 
invasion, migration and suppressing antitumor immunity 
[32, 33]. CD163 is a macrophage-specific scavenger 
receptor that is upregulated by anti-inflammatory inducers 
and is therefore associated with macrophages bearing M2 
features [34]. We established that the number of CD163 
positive macrophages in Chy mice was no different from 
wt littermates. However, the total number of TAMs was 
significantly lower in Chy mice, implying a reduced 
number of anti-tumorigenic M1-activated macrophages to 
facilitate tumor progression. If tumor macrophage numbers 
were reduced therapeutically with liposomal clodronate, 
decreased tumor growth was observed, indicating a 
pro-tumorigenic effect of macrophages. However, the 
unselected killing of TAMs with this treatment [22] does 
not recapitulate the skewed M2/M1 ratio in Chy mice.
In our study, we examined cytokines related to 
inflammation from two different compartments within 
the tumor. Whereas the western blot analysis examined 
the total level of cytokines within the tumor tissue, 
the assessment of tumor interstitial fluid mirrors the 
secreted cytokines mediating signals between cells in 
the extracellular tumor microenvironment. Among seven 
cytokines analyzed in the C3HBA tumor interstitial fluid, 
IL-6 was the only cytokine found to be significantly higher 
in the extracellular microenvironment in Chy tumors. This 
increase appears to be breast cancer-specific since IL-6 
levels were equal in serum and interstitial tissue of non-
tumor bearing Chy and wt mice [12], and in KHT-1 tumors 
with or without the Chy mutation. There are several cell 
types in the tumor microenvironment that potentially could 
secrete IL-6; stromal cells (e.g fibroblast, adipocytes) and 
cancer cells [35, 36]. Indeed, Chy mice are characterized 
by more subcutaneous adipose tissue than their wt 
littermates [10]. It has been previously reported that 
IL-6 is significantly upregulated in peritumoral adipose 
tissue [37] which could explain a higher IL-6 levels in 
these mice. The inflammatory microenvironment created 
by excess adipose tissue has lately received increasing 
attention, and one of the key cytokines in the link between 
obesity and cancer is in fact IL-6 [38]. In addition to 
IL-6 being deposited by the increased adipose tissue, the 
impaired lymphatic washout in Chy mice could potentially 
reduce the washout of locally produced cytokines from 
the tumor microenvironment, thus contributing to the 
increased IL-6 levels in Chy tumors.
Inflammation is recognized as an enabling 
characteristic in cancer development [39] and IL-6 is 
one of several cytokines (IL-1, TNFα, IL-23) found to be 
essential in inflammatory processes and cancer growth 
[40, 41]. It has been reported previously that IL-6 induces 
endothelial cell proliferation [37], but we did not observe 
increased tumor angiogenesis in Chy tumors. IL-6 further 
stimulates myeloid-derived suppressor cells (MDSC) 
[42] and anti-tumor T-cell activity [43]. Furthermore, 
IL-6 mediates monocytes-to-macrophage differentiation 
[44, 45], while activating several known macrophage 
attractants (e.g CCL2, CXCL-12) [46], improving 
macrophage survival after recruitment [47] and polarizing 
them into M2 macrophages [47–49]. In the current report, 
inhibition of IL-6 signaling with tocilizumab yielded 
significant growth retardation, in orthotopic breast cancer, 
implicating IL-6 as a key mediator of tumor progression. 
While tocilizumab treatment inhibited C3HBA tumor 
growth both in Chy and wt mice, the substantially higher 
IL-6 level in Chy tumors indicates that this cytokine is 
relevant for the accelerated tumor growth observed.
Various therapeutic strategies aimed at tumor 
lymphangiogenesis are currently being tested both 
preclinically and clinically [6, 8]. In this regard, a 
pharmacological downregulation of VEGFR-3 would 
simulate the Chy phenotype, and should be tested in the 
early cancer setting experimentally. Our results indicate 
that reduced VEGFR-3 levels could have a detrimental 
effect on the immunological anti-tumor response in an 
early stage of primary tumor growth, through impaired 
lymphangiogenesis and IL-6 elevation. Interestingly, the 
IL-6 receptor antibody tocilizumab could be employed 





Breeding, maintenance and genotyping of 
heterozygous VEGFR-3 mutant mice (Chy mice) were 
performed as described previously [10] . The mice were 
maintained on a C3H background and the breeding 
yielded either Chy mice (VEGFR3+/Chy) or wildtype (wt) 
siblings (VEGFR-3+/+). The mice were anesthetized with 
a mixture of ketamine (12.2 mg/ml; Ketalar, Pfizer) and 
metetomidine (24.3 μg/ml; Domitor, Orion Pharma) during 
micropuncture and wick-in-needle experiments, and with 
1 % isofluorane in a combination with O2 and N2 during 
all other procedures. Animals were euthanized with CO2. 
All animal experiments were conducted in accordance 
with the regulations of the Norwegian State Commission 
for Laboratory Animals, which are consistent with the 
European Convention for the Protection of Vertebrate 
Animals used for Experimental and Other Scientific 
Purposes and Council of Europe (ETS 123). Experiments 
were performed with the approval from the Association for 
Assessment and Accreditation of Laboratory Animal Care 
(AAALAC) International accredited Animal Care and Use 
Program at University of Bergen.
Cell lines and tumor growth experiments
The C3HBA breast cancer cell line was purchased 
from the NCI-Frederick Cancer DCT Tumor Repository 
(Frederick, MD), whereas the KHT-1 sarcoma was a 
kind gift from Professor Michael Horsman (Aarhus, 
Denmark). The tumor cells were grown at 37°C in 5% 
CO2 in Dulbecco’s Modified Eagle’s Medium (DMEM), 
supplemented with non-essential amino acids, 10% 
fetal calf serum, 100 U/ml penicillin, 100 mg/ml of 
streptomycin and 400 uM L-glutamine (all products: 
Lonza).
For implantation of mouse tumors, a tumor tissue 
piece of 1 mm3 was excised from an euthanized animal 
and implanted in the mammary fat pad (C3HBA) or 
s.c in the dorsal neck region (KHT-1). Female mice 
of fertile age were used for the C3HBA breast cancer 
experiment, and male and female mice of fertile 
age were used for the KHT-1 trial. The C3HBA and 
KHT-1 tumors are both syngeneic to C3H mice. For 
the metastasis study, liposomal clodronate and IL-6 
experiment, 5 x 106 cells were injected into the lower 
left mammary fat pad.
Tumor growth was measured at regular intervals 
using vernier calipers. Tumor volumes were calculated 
using the formula (a2b *(π/6)) where a and b are the shorter 
and longer diameters of the tumors respectively. The 
animals were euthanized if they showed signs of serious 
distress or when tumor diameters exceeded 20 mm, in 
accordance with ethical guidelines for animal experiments 
in Norway. The tumor growth time (TGT) was defined as 
the time taken for tumors to reach 2250mm3.
At euthanasia, the tumor tissue was removed for 
further analysis and the lymph nodes and organs were 
examined for the occurrence of metastases. Tissue samples 
were divided in three and either 1) snap-frozen in liquid 
nitrogen and stored at -80°C, 2) snap-frozen in Tissue-Tek 
OCT-compound (Sakura) or 3) formalin-fixed and paraffin 
embedded for immunohistochemistry and subsequent 
analysis.
To ablate tumor macrophages, wt mice were given 
intraperitoneal injections every 96 hours of either 200 μl 
liposomal clodronate or empty liposomes (Encapsula, 
Nano Science) [50]. Treatment commenced the day before 
implanting the mice with C3HBA cells, and continued for 
21 days.
To assess the functional importance of IL-6, Chy 
and wt mice were given daily intraperitoneal injections for 
21 days with either 200 μl saline (0.9% NaCl) (controls) 
or 200 μl of an anti-IL-6 receptor monoclonal antibody 
tocilizumab (RoActemra, Roche) (500 μg/ml) [35].
Lectin perfusion
Blood vessel perfusion was assessed by i.v. injection 
of TRITC-conjugated lectin, as described elsewhere 
[51]. Briefly, 100 μl (1 mg/ml) of TRITC-conjugated 
Lecopersicon esculentum lectin (Vector Laboratories) 
was injected through the tail vein in anesthetized mice. 
Ten minutes later, the mice were euthanized by cervical 
dislocation and perfused with 40 ml phosphate-buffered 
saline (PBS, Sigma). Tumors were harvested and snap-
frozen in OCT medium in liquid nitrogen. Tumor 
perfusion was analyzed microscopically by measuring the 
area of lectin positive vessels in three vascular hot spots 
per tumor at 200x magnification.
eGFP transfection of the C3HBA breast cancer 
cell line
The pWPI plasmid (Addgene), containing the green 
fluorescent protein (eGFP) gene was produced in One 
Shot® Stbl3™ Chemically Competent E. coli (Invitrogen), 
under growth selection of ampicillin (Pentrexyl, Bristol-
Myers Squibb), and positive clones were verified by 
sequencing. HEK293FT cells (Invitrogen) were co-
transfected with envelope plasmid pMD2.g, packaging 
plasmid psPAX2 (Addgene) and the pWPI plasmid, using 
Lipofectamine 2000 (Invitrogen). The fully competent 
lentivirus was harvested and used for transduction of 
C3HBA cells with pWPI. The in vitro transduction 
efficacy was assessed based on eGFP protein expression 
using the NucleoCounterÒ NC-3000TM (Chemometec), 
and the cells were sorted using a BD FACSARIA (BD 
Biosciences) at the Flow Cytometry Core Facility 
(University of Bergen) to enrich for eGFP+ cells.
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RNA extraction and cDNA production
RNA extraction was performed using the mirVanaTM 
kit (Life Technologies). After DNase treatment (DNA-
freeTM kit, Ambion), the RNA concentrations were measured 
using a NanoDrop spectrophotometer (Thermo Scientific), 
and cDNA was made from 500 ng RNA per sample, using 
the qScript cDNA Supermix (Quanta BioSciences). The 
cDNA was then treated with 1 μl RNAse H (Invitrogen) 
to remove remaining RNA. RT-PCR was done using 
AmpliTaq Gold polymerase, and PCR reactions were run 
with 35 cycles and the appropriate temperature settings. A 
β-actin PCR reaction was undertaken to ensure equal cDNA 
content in the samples. All PCR products were checked for 







Lymphatic drainage from the skin directly overlying 
the tumor was assessed by optically monitoring the depot 
clearance of near-infrared labelled albumin as described 
previously [13]. Briefly, 0.5 μl Alexa 680-conjugated bovine 
serum albumin (Invitrogen) was injected intradermally 
with a graded Hamilton syringe (34 G), and the mice 
were optically imaged every 60 min for a 6 hour period 
using an Optix® MX system (GE Healthcare). Mice were 
anesthetized (1% isofluorane) only during imaging and 
remained awake in between measurements. Images were 
analyzed using eXplore Optix Optiview software (GE 
Healthcare), and the number of counts calculated for each 
region of interest. For calculations of depot clearance rates 
(k) the natural logarithm of the fractional amount of counts 
remaining at the injection site was plotted against time. The 
resultant monoexponential curves were fitted with linear 
regression, and k found as the slope of each curve.
Tumor interstitial fluid pressure
Tumor interstitial fluid pressure (IFP) was measured 
in wt and Chy mice using the micropuncture and wick-
in-needle (WIN) techniques, as described previously 
[17]. Briefly, the IFP in superficial areas (0-1 mm depth) 
was recorded in anesthetized mice using a sharpened 
micropipette (diameter; 4-7 μm), connected to a servo-
controlled counter-pressure system that was inserted 
through intact skin (18). To assess the IFP in deep 
intratumoral areas, a 23 G needle with a 2-4 mm side hole 
and filled with nylon fibers and saline (WIN technique), was 
inserted into the central part of the tumor and connected to a 
transducer dome through a saline filled PE-50 catheter [17].
Primary antibodies
Immunohistochemistry/immunofluorescence
Rabbit polyclonal antibodies: LYVE-1 (Abcam), 
CD11b (Abcam), CD163 (Santa Cruz), CD3 (Abcam), 
CD20 (Thermo Fisher), FOXP3 (Abcam). Rat monoclonal 
antibodies: CD31 (Santa Cruz)), CD45 (R&D, BD 
Pharmingen), F4/80 (Abcam, AbD Serotec).
Western blots
Rabbit anti-actin (Sigma), rat anti-IL1-beta/IL-1F2 
(R&D), rabbit anti-TGF-beta (Nordic Biosite), rat anti-GM-
CSF (Abcam), rat anti-IL10 (Abcam), goat anti-M-CSF 
(Abcam), goat anti-VEGFD (Abcam), rabbit anti-VEGF 
(Abcam), rabbit anti-VEGFC (Abcam), rabbit anti-PlGF 
(Abcam), rabbit anti-IL-6 (Abcam), rabbit anti-phospho 
(Ser727) STAT3 (Cell Signaling), rabbit anti-phospho, 
(Tyr705) STAT3 (Cell Signaling), rabbit anti-STAT3 
(Cell Signaling). Anti-GM-CSF, IL-10 and IL-1beta were 
monoclonal antibodies, all other antibodies were polyclonal.
Immunohistochemistry of paraffin embedded 
tissue sections
Tissues were fixed in formalin, paraffin embedded 
and 4 mm sections prepared. Sections were deparaffinized 
and rehydrated, before antigen retrieval at 98°C for 1 
hour in 0.01 M citrate buffer (pH 6.0). After blocking 
with diluted serum from the secondary antibody host 
for 30 min, the slides were incubated overnight (+4°C) 
with the primary antibody. After blocking endogenous 
peroxidase activity for 20 min with 3% hydrogen peroxide 
(Sigma), a biotinylated anti-rat or anti-rabbit secondary 
antibody (Vector Laboratories) was applied for 30 min 
as appropriate. The antigen-antibody complex reaction 
was augmented with avidin-biotin-peroxidase (ABC) 
for 30 min according to the manufacturer’s instructions 
(Vectastain® ABC Kit, Vector), and stained for 2-10 min 
with diamino-benzidine tetrahydrochloride (DAB, Vector). 
The sections were then counterstained with haematoxylin 
(Fisher), dehydrated and mounted with Entellan (Electron 
Microscopy Services). Parallel sections were run for all 
the experiments without primary antibody, to assure the 
specificity of the immunoreactions.
Blood vessel density (BVD) was assessed by 
immunolabeling for CD31, using the microvessel 
density (MVD) method [52]. Briefly, the mean BVD in 
three vascular hot spots per tumor was assessed at 200x 
magnification.
Intratumoral macrophages were quantified by 
immunolabeling with a CD11b antibody, which was the 
only antibody that yielded acceptable staining within 
the tumor tissue, while peritumoral macrophages were 
quantified by immunolabeling with CD11b, F4/80 and a 
CD163 antibody. CD3, CD20 and FOXP3 antibodies were 
used to quantify adaptive immune cells in C3HBA and 
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KHT-1 tumors, but extensive necrotic areas within KHT-
1 tumors yielded too much unspecific staining for these 
parameters to be quantified. The number of cells per field-
of-view was counted in three hot spots at 200x, 400x or 
600x objective magnification.
Western blot
Cells and tissues were homogenized and lysed in a 
custom made total protein lysis buffer (50 mM Tris HCl, 
pH 7.5, 150 mM NaCl, 0.1% SDS, 1% deoxycholate, 
1% Triton X-100) containing a protease and phosphatase 
inhibitor cocktail (Roche, Basel, Switzerland). Protein 
concentrations were measured by a bicinchoninic acid 
(BCA) assay (Pierce), and 30 mg protein was loaded 
per lane for all the immunoblots. The protein lysates 
were fractionated by electrophoresis using NuPAGE 
Novex 4-12% Bis-Tris Gel (Invitrogen) and transblotted 
to nitrocellulose membranes using the XCell II Blot 
Module (Invitrogen). Adequate sample transfer was 
confirmed by staining the blot with Ponseau S solution 
(Sigma). Thereafter the membranes were blocked with 
5% bovine serum albumine (Sigma) for 60 min, before 
immunoblotting overnight with the primary antibody. The 
immobilized antibody was detected using a horseradish 
peroxidase-conjugated secondary antibody and stained 
with SuperSignal West Pico Chemiluminescent Substrate 
(Thermo Scientific). The immunoreaction was visualized 
using a LAS-3000 imaging system (FujiFilm, Tokyo, 
Japan). Immunoblots for actin were made for all samples 
to assure equal protein loading. The western blot protein 
bands were compared by automated densitometry using 
Image J software (NIH, USA).
Sampling and ELISA of tumor interstitial fluid
Interstitial fluid was sampled from tumors in Chy 
and wt mice, as described previously [53]. Briefly, the 
tumor tissue was put on a mesh before centrifugation 
at 424 g for 10 min, yielding 10-50 ml of interstitial 
fluid. The collected fluid samples were stored at -80°C 
prior to analysis. The interstitial fluid was assessed 
for a panel of common inflammatory cytokines using a 
multiplex fluorescent bead immunoassay kit (Millipore) 
and an IL-6 ELISA kit (R&D systems), according to our 
previous protocol [12]. Samples were diluted with serum 
matrix diluent and run according to the manufacturers’ 
instructions. Total surface fluorescence was measured 
with a flow-based dual laser system (Luminex100, Luminex 
Corporation). Cytokine concentrations were automatically 
calculated based on standard curve data.
Statistics
Data were compared using the nonpaired Student’s 
t-test unless otherwise specified. p <0.05 was considered 
statistically significant. In the tocilizumab treatment study, 
data were analyzed using two-way analysis of variance 
(ANOVA).
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